<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00148395</url>
  </required_header>
  <id_info>
    <org_study_id>NSCLC 06/2001</org_study_id>
    <nct_id>NCT00148395</nct_id>
  </id_info>
  <brief_title>Randomized Phase III-Study in Stage IIIb and IV Non-Small-Cell Lung Cancer. Sequential Single-Agent vs. Double-Agent vs. Triple-Agent Therapy.</brief_title>
  <official_title>Randomized Phase III-Study in Stage IIIb and IV Non-Small-Cell Lung Cancer. Sequential Single-Agent vs. Double-Agent vs. Triple-Agent Therapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aktion Bronchialkarzinom e.V.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aktion Bronchialkarzinom e.V.</source>
  <brief_summary>
    <textblock>
      This study wants to assess different intensive therapy sequences for the treatment of
      non-small-cell lung cancer.

      It claims less on the efficacy of different chemotherapy combinations, than more on the
      comparison of different strategies of sequential single-agent, sequential double-agent or
      sequential triple-agent therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2002</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of live</measure>
  </secondary_outcome>
  <enrollment>280</enrollment>
  <condition>Non-Small-Cell Lung Carcinoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Navelbine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitomycin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ifosfamide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histological verified non-small cell lung cancer. Cytological diagnosis is accepted
             for doubtless results.

          2. Present stage IIIb with malignant pleural effusion or stage IV disease. Tumor
             dissemination should not be irradiable in one field

          3. Age between 18 and 75 years

          4. Karnofsky index 70 - 100%

          5. Measurable or evaluable tumor parameter

          6. No prior chemotherapy for NSCLC

          7. Sufficient hematological parameter before start of therapy (leucocytes &gt; 3.500/µl and
             platelets &gt; 100.000/µl).

          8. Sufficient liver function (bilirubin &lt; 1,6mg/dl)

          9. Sufficient renal function (creatinine &lt; 1,5mg/dl and clearance &gt; 60ml/min)

         10. Minimal estimated life expectancy &gt; 3 months

         11. Written informed consent for study attendance

         12. Patient accessibility for therapy and follow up

         13. No attendance to an other study

        Exclusion Criteria:

          1. Small-cell lung cancer oder tumors with small-cell fractions

          2. Local advanced irradiable stage III

          3. Previous chemotherapy because of other diseases, not longer than 3 years ago

          4. Simultaneous radiation of all present tumor manifestations

          5. Simultaneous or not longer than 3 years ago secondary malignancy, except carcinoma in
             situ of the cervix or dermal cancer, others than melanoma

          6. Respiratory insufficiency

          7. Heart insufficiency NYHA III and IV

          8. Peripheral arteriosclerosis stage III and IV

          9. Neurological and psychiatric diseases, which affect understanding of the study concept
             and the possibility to keep conditions of the protocol

         10. Pregnancy, breastfeeding or not ensured contraception

         11. HIV-infection

         12. Active hepatitis B and C

         13. Manifest infectious diseases before start of therapy

         14. Minimal estimated life expectancy &lt; 3 months

         15. No written informed consent of the patient for study attendance and storage and
             disclosure of disease data according to the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Wolf, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Klinikum Kassel GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinikum Kassel GmbH</name>
      <address>
        <city>Kassel</city>
        <zip>34125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2005</study_first_submitted>
  <study_first_submitted_qc>September 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2005</study_first_posted>
  <last_update_submitted>April 21, 2008</last_update_submitted>
  <last_update_submitted_qc>April 21, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2008</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Mitomycins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

